We, therefore, suggest that the effect of dorzagliatin on glucose-stimulated GLP-1 secretion in patients with T2D and obesity is a combination of the role of GK in GLP-1 regulation and the pharmacokinetic property of dorzagliatin with intrinsic high organ distribution in the small intestine. Here, GLP1R is linked to type 2 diabetes mellitus.